GvHD prevention is possible and equally important in patients going through the process of a bone marrow transplant. A drug named abatacept indicated for approved usage of rheumatoid arthritis is currently in news.
This drug has received FDA’s attention because it is potent to be used for the prevention of GvHD. Now the availability of the drug for this new indication in the hospitals is anticipated.
GvHD (Graft versus host disease) is mainly a condition during which the transplanted graft starts reacting against the host. Today Bone marrow transplants are helping in treating several cancers like lymphoma, hashtag leukemia and it even offers a cure for different blood disorders including sickle-cell disease, metabolic disorders, and genetic immunodeficiencies, etc.
But during transplants there arises a high risk of GvHD which can be treated with some available line of treatments but not in every case depending upon severity. GvHD symptoms might vary from case to case from skin rashes, diarrhoea, and even liver damage, etc. So a constant need to prevent GvHD in the first place has now lead to a new prevention approach of using abatacept if approved.